Clinical trials: Hypertension, Pulmonary
Pulmonary Arterial Hypertension
Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric
Study of PAH Subjects with LTOT Use that have Demonstrated Improved Exercise Tolerance with the use of Inhaled Nitric Oxide
- Trial name
- NCT03602781
- Testing
- iNO
- Where
- 4 sites in United States, Canada
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
This is a two-part (Phase 2/Phase 3) study of frespaciguat, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT04732221
- Testing
- Frespaciguat
- Where
- 91 sites in United States, Argentina and 16 more
- Volunteers
- 168 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
The purpose of this study is to assess the effect of BIA 5-1058 200 mg on the pharmacokinetic (PK) of treprostinil
- Trial name
- NCT04675944
- Testing
- BIA 5-1058, treprostinil
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Effects of Oral Sildenafil on Mortality in Adults With PAH
This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]).
- Trial name
- AFFILIATE (NCT02060487)
- Testing
- sildenafil citrate
- Where
- 82 sites in United States, Australia and 21 more
- Volunteers
- 385 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.
- Trial name
- Epitome2ext (NCT01470144)
- Testing
- Epoprostenol
- Volunteers
- 41 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers
This study is designed to investigate the safety and tolerability of AIR001 Inhalation Solution when administered under conditions of hypoxia and to identify dose levels of drug resulting in a reduction in pulmonary arterial…
- Trial name
- AIR001-CS02 (NCT00814645)
- Testing
- Sodium Nitrite Inhalation Solution
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Aires Pharmaceuticals, Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH)…
- Trial name
- NCT00796510
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 3 sites in United States, Romania and 1 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Pulmonary Fibrosis, Pulmonary Hypertension
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled dose escalation study to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis on long term oxygen therapy.
- Trial name
- NCT05747508
- Testing
- INOpulse®, Long Term Follow Up
- Where
- 23 sites in United States
- Volunteers
- 85 people
- Sponsor
- Bellerophon
Pulmonary Hypertension, Pulmonary Fibrosis
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
This multicenter, randomized, open-label study will assess the safety and efficacy of oral treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary fibrosis.
- Trial name
- NCT02603068
- Testing
- Oral treprostinil
- Where
- 7 sites in United States
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308.
- Trial name
- FREEDOM-EXT (NCT01027949)
- Testing
- Oral Treprostinil
- Where
- 134 sites in United States, Australia and 18 more
- Volunteers
- 894 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
The purpose of this trial was to establish the safety, tolerability and PK of nilotinib in this population and to test the hypothesis that 6 months treatment with nilotinib will significantly reduce pulmonary artery resistance.
- Trial name
- NCT01179737
- Testing
- Nilotinib
- Where
- 13 sites in United States, Canada and 4 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with…
- Trial name
- UNISUS (NCT04273945)
- Testing
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg
- Where
- 274 sites in United States, Argentina and 40 more
- Volunteers
- 935 people
- Sponsor
- Actelion
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
The purpose of this study is to establish single-dose tolerability of inhaled treprostinil sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to explore the acute hemodynamic effects over a…
- Trial name
- NCT00703339
- Testing
- Treprostinil sodium for inhalation
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
OPsumit USers Registry
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with…
- Trial name
- OPUS (NCT02126943)
- Testing
- Opsumit (macitentan)
- Where
- 146 sites in United States, Puerto Rico
- Volunteers
- 2,686 people
- Sponsor
- Actelion
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Pulmonary Hypertension Associated With Interstitial Lung Disease
Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
This Phase 3 study is designed as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE) period.
- Trial name
- SERANATA (NCT07181382)
- Testing
- Seralutinib, Generic Dry Powder Inhaler
- Where
- 4 sites in United States, Israel
- Volunteers
- 480 people
- Sponsor
- GB002, Inc.
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
Berlin Cures develops BC 007 to treat patients suffering from diseases (chronic heart failure, pulmonary hypertension, chronic fatigue syndrome etc.) which are associated with functional autoantibodies (AAB) directed against…
- Trial name
- NCT02955420
- Testing
- BC 007, NaCl 0.9 %
- Where
- Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Berlin Cures GmbH
Anemia, Diabetes, Kidney Disease, Chronic, Hypertension
Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan
The purpose of this study is to evaluate the prevalence of CKD-related anemia at an early stage through screening of high-risk patients in Pakistan at the level of physicians, cardiologists, and diabetologists.
- Trial name
- NCT02444845
- Where
- 3 sites in Pakistan
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Arterial Hypertension
Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler)
This is a non-invasive study using a standard doppler echocardiographic transducer which records signals emanating from the lungs (TPD). These signals are caused by pulsation of blood vessels in the lung tissue.
- Trial name
- NCT01357746
- Testing
- Transthoracic pulmonary doppler recording
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Echosense Ltd.